MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel therapeutics for the treatment of diseases with unmet medical needs and a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes clinical-stage compounds for the treatment of progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, acute respiratory distress syndrome (ARDS), nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia. MediciNova’s current strategy is to focus on MN-166 (ibudilast) for neurological and other disorders, and MN-001 (tipelukast) for fibrotic and metabolic disorders. MediciNova may pursue development independently or establish a strategic collaboration to support further development of its programs. MediciNova will seek to monetize its other product candidates at key value inflection points. MediciNova’s executive management team has extensive global development, regulatory, commercial and financial experience, and manages its international clinical and manufacturing operations through efficient and cost-effective utilization of contract research organizations. MediciNova is headquartered in La Jolla, California.